Nivolumab plus Ipilimumab in Microsatellite-Instability–High (MSI-H) Metastatic Colorectal Cancer

In this episode of the Oncology Brothers podcast, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Nicholas Hornstein, a GI medical oncologist from Northwell Health, to discuss the recent FDA approval of nivolumab and ipilimumab for metastatic colorectal cancer with MSI-high or MMR-deficient disease, based on the CheckMate 8HW study.

Join us as we delve into:
•⁠  ⁠The significance of MSI-high status in colorectal cancer and its prevalence.
•⁠  ⁠The study design and key findings of CheckMate 8HW, including the impressive progression-free survival rates.
•⁠  ⁠The comparison of dual checkpoint inhibitors versus single-agent therapies and chemotherapy.
•⁠  ⁠Important side effects associated with the combination therapy and how to manage them.
•⁠  ⁠Insights on patient selection for immunotherapy, including considerations for age and comorbidities.
•⁠  ⁠The potential future of immunotherapy in treating not just MSI-high but also MSS colorectal cancer.

Whether you're a healthcare professional or simply interested in the latest advancements in oncology, this episode provides valuable insights into the evolving landscape of cancer treatment.

YouTube: https://youtu.be/wJRlECiY2VA

Follow us on social media:
•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers
•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers
•⁠  Website: https://oncbrothers.com/

Don't forget to like, subscribe, and check out our previous episodes for more discussions on FDA approvals, conference highlights, and treatment algorithms. We look forward to seeing you at ASCO 2025!
#OncologyBrothers #CancerPodcast #Immunotherapy #ColorectalCancer #FDAApproval #CheckMate8HW